Celgene ( Celgene )


Celgene's picture

About Celgene

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Celgene press release, blog etc

10/10/2018 - 20:33 Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy
10/10/2018 - 10:35 New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
10/08/2018 - 10:27 Celgene Announces Phase 3 STYLE Study of OTEZLA (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
09/13/2018 - 23:18 The Goal to Treat Lymphoma without Chemotherapy
09/12/2018 - 11:55 OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
09/03/2018 - 20:26 Bound by Blood: Continuing to Deepen Our Bonds with Blood Cancer Patients
07/24/2018 - 19:21 Building on Research on Immunomodulator Regimens in Relapsed Multiple Myeloma Treatment
07/22/2018 - 23:01 Celgene Announces Phase III AUGMENT' Study of REVLIMID in Combination with Rituximab (R) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint
07/10/2018 - 12:25 Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
07/09/2018 - 12:54 Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia
06/29/2018 - 23:08 California Declaration of Compliance
06/28/2018 - 09:23 Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
06/03/2018 - 08:30 Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
06/02/2018 - 16:38 We Cant Afford Not To Innovate and Provide Access to the Best Multiple Myeloma Care Possible
06/02/2018 - 10:54 CAR T Cell Research Continues to Advance
06/01/2018 - 09:35 Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
05/31/2018 - 08:14 Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy Officer
05/30/2018 - 02:50 MS Progression Linked to Grey Matter Atrophy